Related Experiment Video
Updated: Jul 15, 2025
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.5K
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara1, Ashmita Mazumder2, Yusra Syeda3
1Department of Human Genetics, University of Michigan Medical School, Ann Arbor, USA.
Advances in Medicine
|September 29, 2023
Summary
The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for weight management is increasing. This review highlights the importance of understanding off-label prescribing practices and medication effects for informed patient and physician decisions.
Area of Science:
- Pharmacology
- Endocrinology
- Public Health
Background:
- Rising global obesity rates necessitate effective weight management strategies.
- Pharmaceutical weight-loss drugs, particularly GLP-1 agonists, have gained significant market popularity.
- GLP-1 agonists are also established treatments for type 2 diabetes.
Purpose of the Study:
- To review the increasing trend of off-label prescribing of GLP-1 agonists for weight management.
- To examine the efficacy and safety considerations of these medications in weight management.
- To emphasize informed decision-making for physicians and patients regarding weight-loss pharmacotherapy.
Main Methods:
- Literature review of clinical trials and research on GLP-1 agonists for weight management.
- Analysis of prescribing patterns, focusing on off-label use.
- Synthesis of evidence regarding efficacy, safety, and patient outcomes.
Main Results:
- GLP-1 agonists are frequently prescribed off-label for weight loss.
- Growing body of research supports their efficacy but also highlights the need for long-term safety data.
- Off-label use presents unique considerations for clinical practice.
Conclusions:
- Physicians and patients must be aware of the implications of off-label GLP-1 agonist use for weight management.
- Informed decision-making is crucial, balancing potential benefits against risks.
- Further research is needed to guide optimal clinical practice and policy for weight-loss pharmacotherapy.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
01:06Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
01:23Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
01:15Hypoglycemia and Glucagon
287
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
287
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196